Ashwagandha for subclinical hypothyroidism - normalization of TSH
Ashwagandha for subclinical hypothyroidism: a reliable response based on research. u Bucha.
TSH result slightly above normal, but T3 and T4 are normal. The doctor says, "we are monitoring." You feel fatigued. This is a typical scenario of subclinical hypothyroidism - a condition affecting 4 to 8 percent of adults and which conventional medicine most often treats with watchful waiting. In 2018, a randomized clinical trial was published to check whether ashwagandha root extract could affect TSH levels. The results were surprising. In this article, we analyze this study reliably - without exaggeration in either direction - and explain for whom this knowledge is practically useful.
KEY INFORMATION
• One RCT (n=50, 8 weeks) showed that 600 mg of KSM-66 ashwagandha extract daily significantly reduced TSH and increased T3 and T4 in patients with subclinical hypothyroidism (Sharma et al., JACM, 2018).
• Subclinical hypothyroidism (TSH 4.5-10 mIU/L, normal T3/T4) affects 4-8% of the general population, and in women over 60, even 15-20%.
• Ashwagandha does not replace levothyroxine - the study concerned only the subclinical state.
• Individuals with Hashimoto's disease or Graves' disease should consult an endocrinologist before using.
What is subclinical hypothyroidism?
Subclinical hypothyroidism (SCH) is defined as elevated TSH (above 4.5 mIU/L) with normal levels of T3 and T4 in the blood. Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and serves as a sensitive indicator that the thyroid is functioning below the expectations of the pituitary - even if the thyroid hormones themselves are still within the normal range (Biondi et al., New England Journal of Medicine, 2019).
The epidemiology of SCH is significant. Meta-analyses indicate a prevalence of 4-8% in the general population, but among women over 60, this percentage rises to 15-20%. Many patients are asymptomatic and are diagnosed incidentally. However, some individuals report nonspecific symptoms: fatigue, difficulty concentrating, weight gain, and feeling cold. It is this gray area between 'health' and 'disease' that attracts interest in complementary therapies.
The decision to use pharmacological treatment (levothyroxine) is controversial. Current guidelines from the European Thyroid Association recommend treatment mainly when TSH is above 10 mIU/L or in the presence of clear clinical symptoms. For TSH levels of 4.5-10 mIU/L - typical for SCH - the standard is observation and monitoring every 6-12 months.
What did the only RCT on ashwagandha and the thyroid show?
The study by Sharma and colleagues published in Journal of Alternative and Complementary Medicine in 2018 is the only randomized, double-blind, placebo-controlled trial directly testing the effect of ashwagandha on thyroid function in humans (Sharma et al., JACM, 2018). It included 50 patients with confirmed SCH, randomly assigned to receive either 600 mg of KSM-66 extract or placebo for 8 weeks.
The results were statistically significant. In the ashwagandha group, TSH decreased from a median of 5.93 to 4.80 mIU/L (p<0.001), while no significant changes were observed in the placebo group. At the same time, levels of T3 (triiodothyronine) and T4 (thyroxine) significantly increased in the active group. This suggests that ashwagandha may modulate the pituitary-thyroid axis, although the mechanism is not yet fully understood.
| Parameter | Before (ashwagandha) | After 8 weeks (ashwagandha) | Placebo change |
|---|---|---|---|
| TSH (mIU/L) | 5,93 | 4,80 | No significant change |
| T3 (ng/dL) | ↑ significantly | Wzrost p<0,001 | No significant change |
| T4 (μg/dL) | ↑ significantly | Wzrost p<0,001 | No significant change |
We noticed that this study is regularly cited online without a key caveat: it involved only 50 participants. In evidence-based medicine, the result of one small RCT - even if well-designed - requires replication in larger trials before it becomes the basis for clinical recommendations. This does not undermine the results but sets a boundary on the certainty we can place in them.
How can ashwagandha affect the thyroid? Proposed mechanisms
Researchers propose several mechanisms through which withanolides (the active components of ashwagandha) may modulate thyroid function. The first is the adaptogenic effect on the HPA axis (hypothalamus-pituitary-adrenal): cortisol inhibits the conversion of T4 to active T3, so lowering cortisol through ashwagandha may indirectly increase the availability of active thyroid hormones. Studies consistently confirm that KSM-66 reduces cortisol by 25-30% (Chandrasekhar et al., Indian Journal of Psychological Medicine, 2012).
The second mechanism concerns the direct effect on the pituitary. Withanolides have a steroid-like structure and may interact with hormonal receptors, potentially including the TSH receptor or pathways regulating TSH synthesis. This is a hypothesis still requiring confirmation in mechanistic studies.
The third pathway: ashwagandha exhibits immunomodulatory properties. Since a significant portion of subclinical hypothyroidism has an autoimmune basis (Hashimoto's disease with anti-TPO antibodies), modulation of the immune system could theoretically affect the intensity of the immune attack on the thyroid. However, this is speculation - Sharma's study did not measure anti-TPO antibodies.
For whom might ashwagandha be a reasonable option for SCH - and for whom not?
The decision to use ashwagandha for SCH should be individualized and consulted with a physician. Based on available data, general guidelines can be outlined: ashwagandha may be considered for adults with confirmed SCH (TSH 4.5-10), without pharmacological treatment, without active autoimmune thyroid disease in an exacerbation phase, as part of a controlled, time-limited experiment under medical supervision.
Groups for whom ashwagandha is particularly risky in thyroid issues: individuals with hyperthyroidism or Graves' disease (ashwagandha may increase hormone production), individuals taking thyroid medications (pharmacokinetic interactions are not excluded), pregnant women (ashwagandha is generally discouraged during pregnancy), and individuals with active thyroid cancer.
From our editorial experience: questions about ashwagandha and the thyroid arise very frequently among readers aged 40-60 who have TSH levels around 5-6 and are looking for an alternative to 'just observation'. This is understandable. However, we emphasize: a single study involving 50 participants is not a sufficient basis for self-experimentation - especially with hormonal disorders, where self-diagnosis can be misleading.
Ashwagandha and other methods supporting the thyroid - what to combine, what to avoid?
Subclinical hypothyroidism rarely occurs in isolation - it is often accompanied by deficiencies in selenium, iodine, or iron, which are cofactors essential for the synthesis and activation of thyroid hormones. Selenium is particularly important: it participates in the conversion of T4 to active T3 via selenium-containing deiodinases. Selenium deficiency in patients with SCH may exacerbate symptoms regardless of TSH levels (Ventura et al., International Journal of Endocrinology, 2017).
Which supplements should not be combined with ashwagandha in thyroid issues? Primarily high doses of iodine (e.g., seaweed, kelp in capsules) - excess iodine can paradoxically exacerbate autoimmune thyroiditis through the Wolff-Chaikoff effect. Preparations containing desiccated thyroid extract may have additive interactions with ashwagandha affecting T3/T4. High doses of biotin (above 5 mg/day) can skew TSH test results using immunoassay methods - if you are monitoring TSH while supplementing with ashwagandha, stop biotin 48-72 hours before testing.
What can synergistically support thyroid function alongside ashwagandha? Selenium (55-200 mcg daily) and vitamin D (in cases of confirmed deficiency) have the best evidence as immunological support in Hashimoto's. Zinc is involved in the synthesis of TSH and thyroid hormone receptors. Magnesium supports the conversion of T4 to T3. None of these substances 'cure' the thyroid, but supplementing documented deficiencies is a rational element of comprehensive care.
Frequently Asked Questions
Does ashwagandha really normalize TSH?
One randomized placebo-controlled study showed that 600 mg of standardized KSM-66 extract daily for 8 weeks significantly lowered TSH and increased T3 and T4 in patients with SCH (Sharma et al., JACM, 2018). These encouraging results are based on one small study (n=50) - they require replication in larger trials before becoming the basis for recommendations.
What is subclinical hypothyroidism and who suffers from it?
Subclinical hypothyroidism is a condition of elevated TSH (4.5-10 mIU/L) with normal T3 and T4. It affects 4-8% of the general population, and among women over 60, even 15-20% (Biondi et al., NEJM, 2019). Many patients have no symptoms, while some experience fatigue and difficulty concentrating.
What dose of ashwagandha is used in thyroid studies?
In the only published RCT concerning the thyroid, 600 mg of KSM-66 extract standardized to a minimum of 5% withanolides was used daily, administered in two doses of 300 mg each in the morning and evening. The intervention duration was 8 weeks. There is no data on long-term efficacy beyond 3 months for this indication.
Is ashwagandha safe for thyroid diseases?
Ashwagandha is generally well tolerated for short-term use (up to 12 weeks). However, there have been case reports of increased T3/T4 levels in individuals taking ashwagandha, including cases of thyrotoxicosis. Individuals with Hashimoto's, Graves' disease, or those taking thyroid medications should definitely consult an endocrinologist before using it.
How long should one take ashwagandha to see effects on TSH?
In Sharma's study, significant changes were observed after 8 weeks. Other studies on cortisol and stress indicate initial effects after 4-8 weeks of regular use. There is no data on the long-term efficacy and safety of using ashwagandha specifically for the thyroid beyond 3 months.
Can ashwagandha replace levothyroxine?
No. Ashwagandha is not a medication and in no way replaces hormone replacement therapy. The study concerned only the subclinical state (TSH 4.5-10). Clinical hypothyroidism requires levothyroxine. Using a supplement as an alternative to treatment may lead to delays in appropriate therapy.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
